http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104212440-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C09K11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 |
| filingDate | 2014-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104212440-B |
| titleOfInvention | One class quinazoline ditosylate salt fluorescent probe and Synthesis and applications thereof |
| abstract | The invention discloses class quinazoline ditosylate salt fluorescent probe and preparation method thereof, this fluorescent probe structure is fluorescein-labeled Gefitinib (Gefitinib), and it has stronger inhibit activities to EGFR protein kinase, has potential cancer therapy effect; Confocal fluorescent imaging results is distributed on cytolemma, can be used for imaging cancerous after showing this fluorescent probe and various kinds of cell strain effect.Cells were tested by flow cytometry result shows being proportionate property of EGFR content in cell fluorescence intensity intensification factor and cell.By Fluorescein activated cell sorter, the relative quantification that this fluorescent probe can be applied to biomarker EGFR in cell detects, for cancer diagnosis provides more direct information.Because this fluorescent probe has cancer diagnosis and treatment function concurrently, and can direct-detection viable cell, analyze quick, easy and simple to handle, cost is low, has development and application values. |
| priorityDate | 2014-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 74.